Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells

Elif ERTÜRK, (Bursa Uludağ Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Bursa, Türkiye)
Ferda ARI, (Bursa Uludağ Üniversitesi, Fen ve Sanat Fakültesi, Biyoloji Bölümü, Bursa, Türkiye)
Oğuzhan AKGÜN, (Bursa Uludağ Üniversitesi, Fen ve Sanat Fakültesi, Biyoloji Bölümü, Bursa, Türkiye)
Engin ULUKAYA, (İstinye Üniversitesi, Tıp Fakültesi, Klinik Biyokimya Anabilim Dalı, İstanbul, Türkiye)
Cem İsmail KÜÇÜKALİ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul, Türkiye)
ŞAKİR ÜMİT ZEYBEK (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Moleküler Tıp Anabilim Dalı, İstanbul, Türkiye)
Turkish Journal of Biology
1 0
Yıl: 2021 Cilt: 45 Sayı: 5 Sayfa Aralığı: 613 - 623 Metin Dili: İngilizce DOI: 10.3906/biy-2103-46 İndeks Tarihi: 07-06-2022

Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells

Öz:
Understanding of the functions of microRNAs in breast cancer and breast cancer stem cells have been a hope for the development of new molecular targeted therapies. Here, it is aimed to investigate the differences in the expression levels of let-7a, miR10b, miR-21, miR-125b, miR-145, miR-155, miR-200c, miR-221, miR-222 and miR-335, which associated with gene and proteins in MCF-7 (parental) and MCF-7s (Mammosphere/stem cell-enriched population/CD44+/CD24-cells) cells treated with paclitaxel. MCF7s were obtained from parental MCF-7 cells. Cytotoxic activity of paclitaxel was determined by ATP assay. Total RNA isolation and cDNA conversion were performed from the samples. Changes in expression levels of miRNAs were examined by RT-qPCR. Identified target genes and proteins of miRNAs were analyzed with RT-qPCR and western blot analysis, respectively. miR-125b was significantly expressed (2.0946-fold; p = 0.021) in MCF-7s cells compared to control after treatment with paclitaxel. Downregulation of SMO, STAT3, NANOG, OCT4, SOX2, ERBB2 and ERBB3 and upregulation of TP53 genes were significant after 48 h treatment in MCF-7s cells. Protein expressions of SOX2, OCT4, SMAD4, SOX2 and OCT4 also decreased. Paclitaxel induces miR-125b expression in MCF-7s cells. Upregulation of miR-125b may be used as a biomarker for the prediction of response to paclitaxel treatment in breast cancer.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Adhami M, Haghdoost AA, Sadeghi B, Malekpour Afshar R (2018). Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer 25 (2): 198–205. doi: 10.1007/ s12282-017-0814-8
  • Akgun O, Erkisa M, Ari F (2019). Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells. Journal of Cellular Biochemistry 120 (9): 15467-15482. doi: 10.1002/jcb.28813
  • Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D et al. (1995). Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Research 55 (22): 5276–5282. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/7585588
  • Ari F, Napieralski R, Ulukaya E (2013). Changes in gene methylation following chemotherapy in breast cancer cell lines. Turkish Journal of Biochemistry 38 (2): 34–42. doi: 10.5505/ tjb.2013.46320
  • Aztopal N, Erkisa M, Erturk E, Ulukaya E, Tokullugil AH et al. (2018). Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells. Chemico-Biological Interactions 280 51–58. doi: 10.1016/j.cbi.2017.12.003
  • Banzhaf-Strathmann J, Edbauer D (2014). Good guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell Communication and Signaling 12 (1): 30. doi: 10.1186/1478- 811X-12-30
  • Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 40 (5): 499–507. doi: 10.1038/ng.127
  • Bertoli G, Cava C, Castiglioni I (2015). Micrornas: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics, 5 (10): 1122–1143. doi: 10.7150/thno.11543
  • Bertoli G, Cava C, Castiglioni I (2016). The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer. Scandinavian Journal of Clinical and Laboratory Investigation 76: S34–S39. doi: 10.1080/00365513.2016.1208444
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68 (6): 394– 424. doi: 10.3322/caac.21492
  • Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer 6 (11): 857–866. doi: 10.1038/ nrc1997
  • Chen J, Ren Q, Cai Y, Lin T, Zuo W et al. (2018). Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1. Biochemical and Biophysical Research Communications 501 (1): 212–219. doi: 10.1016/j.bbrc.2018.04.218
  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL et al. (2014). Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncology Reports 31 (1): 376–383. doi: 10.3892/or.2013.2847
  • Czerwinska P, Kaminska B (2015). Regulation of breast cancer stem cell features. Wspolczesna Onkologia 1A: A7–A15. doi: 10.5114/wo.2014.47126
  • Dexter SJ, Cámara M, Davies M, Shakesheff KM (2003). Development of a bioluminescent ATP assay to quantify mammalian and bacterial cell number from a mixed population. Biomaterials 24 (1): 27–34. doi: 10.1016/S0142-9612(02)00239-9
  • Emmrich S, Rasche M, Schöning J, Reimer C, Keihani S et al. (2014). miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes and Development 28 (8): 858–874. doi: 10.1101/gad.233791.113
  • Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G et al. (2014). Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Molecular and Cellular Biochemistry 395 (1–2): 77–88. doi: 10.1007/s11010-014-2113-4
  • Flatmark K, Høye E, Fromm B (2016). microRNAs as cancer biomarkers. Scandinavian Journal of Clinical and Laboratory Investigation 76: S80–S83. doi: 10.1080/00365513.2016.1210330
  • Galoczova M, Coates P, Vojtesek B (2018). STAT3, stem cells, cancer stem cells and p63. Cellular and Molecular Biology Letters 23 (1): 12. doi: 10.1186/s11658-018-0078-0
  • Guo J, He K, Zeng H, Shi Y, Ye P et al. (2019). Differential microRNA expression profiles determined by next-generation sequencing in three fulvestrant-resistant human breast cancer cell lines. Oncology Letters 17 (4): 3765–3776. doi: 10.3892/ ol.2019.10061
  • Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM (2008). MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European Journal of Cancer 44 (18): 2753–2759. doi: 10.1016/j.ejca.2008.09.037
  • Kong F, Sun C, Wang Z, Han L, Weng D et al. (2011). miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. Journal of Huazhong University of Science and Technology - Medical Science 31 (4): 543–549. doi: 10.1007/s11596-011-0487-z
  • Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, HernandezGarcia S et al. (2012). Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31 (11): 1354– 1365. doi: 10.1038/onc.2011.338
  • Lengerke C, Fehm T, Kurth R, Neubauer H, Scheble V et al. (2011). Expression of the embryonic stem cell marker SOX2 in earlystage breast carcinoma. BMC Cancer 11. doi: 10.1186/1471- 2407-11-42
  • Ling H, Fabbri M, Calin GA (2013). MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nature Reviews Drug Discovery 12 (11): 847–865. doi: 10.1038/nrd4140
  • Liu NN, Xi Y, Callaghan MU, Fribley A, Moore-Smith L et al. (2014). SMAD4 is a potential prognostic marker in human breast carcinomas. Tumor Biology 35 (1): 641–650. doi: 10.1007/ s13277-013-1088-1
  • Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25 (4): 402–408. doi: 10.1006/meth.2001.1262
  • Loh HY, Norman BP, Lai KS, Rahman NMANA, Alitheen NBM et al. (2019). The regulatory role of microRNAs in breast cancer. International Journal of Molecular Sciences 20 (19): 4940. doi: 10.3390/ijms20194940
  • Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017). The different mechanisms of cancer drug resistance: A brief review. Advanced Pharmaceutical Bulletin 7 (3): 339–348. doi: 10.15171/apb.2017.041
  • Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN et al. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research and Treatment 136 (2): 331– 345. doi: 10.1007/s10549-012-2289-9
  • Mertins SD (2014). Cancer stem cells: A systems biology view of their role in prognosis and therapy. Anti-Cancer Drugs 25 (4): 353–367. doi: 10.1097/CAD.0000000000000075
  • Nagata T, Shimada Y, Sekine S, Hori R, Matsui K et al. (2014). Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 21 (1): 96–101. doi: 10.1007/s12282-012-0357-y
  • Nie J, Jiang HC, Zhou YC, Jiang B, He WJ et al. (2019). MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT. Bioscience Biotechnology and Biochemistry 83 (6): 1062– 1071. doi: 10.1080/09168451.2019.1584521
  • Phi LTH, Sari IN, Yang YG, Lee SH, Jun N et al. (2018). Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells International 2018. doi: 10.1155/2018/5416923
  • Prabhu KS, Raza A, Karedath T, Raza SS, Fathima H et al. (2020). Non-coding RNAs as regulators and markers for targeting of breast cancer and cancer stem cells. Cancers 12 (2): 351. doi: 10.3390/cancers12020351
  • Samli H, Samli M, Vatansever B, Ardicli S, Aztopal N et al. (2019). Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines. World Journal of Urology 37 (6): 1117–1126. doi: 10.1007/s00345-018-2501-6
  • Uhlmann C, Kuhn LM, Tigges J, Fritsche E, Kahlert UD (2020). Efficient Modulation of TP53 Expression in Human Induced Pluripotent Stem Cells. Current Protocols in Stem Cell Biology 52 (1): 102. doi: 10.1002/cpsc.102
  • Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicology in Vitro 22 (1): 232–239. doi: 10.1016/j. tiv.2007.08.006
  • Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L et al. (2015). MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Research 17 (1): 13. doi: 10.1186/s13058- 015-0515-1
  • Visone R, Croce CM (2009). MiRNAs and cancer. American Journal of Pathology 174 (4): 1131–1138. doi: 10.2353/ ajpath.2009.080794
  • Wang S, Huang J, Lyu H, Lee CK, Tan J et al. (2013). Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death and Disease 4 (3): 556. doi: 10.1038/cddis.2013.79
  • Wang Y, Zeng G, Jiang Y (2020). The emerging roles of MiR-125b in cancers. Cancer Management and Research 12: 1079–1088. doi: 10.2147/CMAR.S232388
  • Zeniou M, Nguekeu-Zebaze L, Dantzer F (2019). Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond. Biochemical Pharmacology 167: 107–115. doi: 10.1016/j.bcp.2019.06.012
  • Zhao S, Yuan Q, Hao H, Guo Y, Liu S et al. (2011). Expression of OCT4 pseudogenes in human tumours: Lessons from glioma and breast carcinoma. Journal of Pathology 223 (5): 672–682. doi: 10.1002/path.2827
  • Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST et al. (2015). MicroRNA125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology 62 (3): 801–815. doi: 10.1002/hep.27887
APA Ertürk E, Ari F, akgün o, Ulukaya E, Kucukali C, ZEYBEK U (2021). Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. , 613 - 623. 10.3906/biy-2103-46
Chicago Ertürk Elif,Ari Ferda,akgün oğuzhan,Ulukaya Engin,Kucukali Cem Ismail,ZEYBEK Umit Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. (2021): 613 - 623. 10.3906/biy-2103-46
MLA Ertürk Elif,Ari Ferda,akgün oğuzhan,Ulukaya Engin,Kucukali Cem Ismail,ZEYBEK Umit Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. , 2021, ss.613 - 623. 10.3906/biy-2103-46
AMA Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. . 2021; 613 - 623. 10.3906/biy-2103-46
Vancouver Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. . 2021; 613 - 623. 10.3906/biy-2103-46
IEEE Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U "Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells." , ss.613 - 623, 2021. 10.3906/biy-2103-46
ISNAD Ertürk, Elif vd. "Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells". (2021), 613-623. https://doi.org/10.3906/biy-2103-46
APA Ertürk E, Ari F, akgün o, Ulukaya E, Kucukali C, ZEYBEK U (2021). Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. Turkish Journal of Biology, 45(5), 613 - 623. 10.3906/biy-2103-46
Chicago Ertürk Elif,Ari Ferda,akgün oğuzhan,Ulukaya Engin,Kucukali Cem Ismail,ZEYBEK Umit Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. Turkish Journal of Biology 45, no.5 (2021): 613 - 623. 10.3906/biy-2103-46
MLA Ertürk Elif,Ari Ferda,akgün oğuzhan,Ulukaya Engin,Kucukali Cem Ismail,ZEYBEK Umit Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. Turkish Journal of Biology, vol.45, no.5, 2021, ss.613 - 623. 10.3906/biy-2103-46
AMA Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. Turkish Journal of Biology. 2021; 45(5): 613 - 623. 10.3906/biy-2103-46
Vancouver Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells. Turkish Journal of Biology. 2021; 45(5): 613 - 623. 10.3906/biy-2103-46
IEEE Ertürk E,Ari F,akgün o,Ulukaya E,Kucukali C,ZEYBEK U "Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells." Turkish Journal of Biology, 45, ss.613 - 623, 2021. 10.3906/biy-2103-46
ISNAD Ertürk, Elif vd. "Investigation of the efficacy of paclitaxel on some miRNAs profiles in breast cancer stem cells". Turkish Journal of Biology 45/5 (2021), 613-623. https://doi.org/10.3906/biy-2103-46
Sayfa Oluşturulma Tarihi
23-04-2024 22:55

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları